Literature DB >> 31299263

Coated cationic lipid-nanoparticles entrapping miR-660 inhibit tumor growth in patient-derived xenografts lung cancer models.

Massimo Moro1, Daniela Di Paolo2, Massimo Milione3, Giovanni Centonze1, Viviana Bornaghi1, Cristina Borzi1, Paolo Gandellini4, Patrizia Perri2, Ugo Pastorino5, Mirco Ponzoni2, Gabriella Sozzi1, Orazio Fortunato6.   

Abstract

Lung cancer is the leading cause of cancer-related deaths. Late diagnosis and inadequate therapies contribute to poor outcomes. MicroRNAs (miRNAs) are small non-coding RNAs and are involved in lung cancer development. Because miRNAs simultaneously regulate several cancer-related genes, they represent an interesting therapeutic approach for cancer treatment. We have developed Coated Cationic Lipid-nanoparticles entrapping miR-660 (CCL660) and intraperitoneally administered (1.5 mg/Kg) twice a week for four weeks into SCID mice carrying subcutaneously lung cancer Patients Derived Xenografts (PDXs). Obtained data demonstrated that miR-660 is down-regulated in lung cancer patients and that its replacement inhibited lung cancer growth by inhibiting the MDM2-P53 axis. Furthermore, systemic delivery of CCL660 increased miRNA levels in tumors and significantly reduced tumor growth in two different P53 wild-type PDXs without off-target effects. MiR-660 administration reduced cancer cells proliferation by inhibiting MDM2 and restoring P53 function and its downstream effectors such as p21. Interestingly, anti-tumoral effects of CCL660 also in P53 mutant PDXs but with a functional p21 pathway were observed. Stable miR-660 expression inhibited the capacity of H460 metastatic lung cancer cells to form lung nodules when injected intravenously into SCID mice suggesting a potential role of miR-660 in metastatic dissemination. To investigate the potential toxic effects of both miRNAs and delivery agents, an in vitro approach revealed that miR-660 replacement did not induce any changes in both mouse and human normal cells. Interestingly, lipid-nanoparticle delivery of synthetic miR-660 had no immunological off-target or acute/chronic toxic effects on immunocompetent mice. Altogether, our results highlight the potential role of coated cationic lipid-nanoparticles entrapping miR-660 in lung cancer treatment without inducing immune-related toxic effects.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lipid-nanoparticles; Lung cancer; P53; Patient-derived xenografts; microRNA

Year:  2019        PMID: 31299263     DOI: 10.1016/j.jconrel.2019.07.006

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  12 in total

Review 1.  Host miRNA and immune cell interactions: relevance in nano-therapeutics for human health.

Authors:  Yogesh Sharma; Adesh K Saini; Sheetal Kashyap; Gourav Chandan; Narinder Kaur; Vijai Kumar Gupta; Vijay Kumar Thakur; Vipin Saini; Reena V Saini
Journal:  Immunol Res       Date:  2021-10-29       Impact factor: 2.829

Review 2.  The emergence of nanoporous materials in lung cancer therapy.

Authors:  Deepika Radhakrishnan; Shan Mohanan; Goeun Choi; Jin-Ho Choy; Steffi Tiburcius; Hoang Trung Trinh; Shankar Bolan; Nikki Verrills; Pradeep Tanwar; Ajay Karakoti; Ajayan Vinu
Journal:  Sci Technol Adv Mater       Date:  2022-07-20       Impact factor: 7.821

Review 3.  A perspective to weaponize microRNAs against lung cancer.

Authors:  Dhanashree Murugan; Loganathan Rangasamy
Journal:  Noncoding RNA Res       Date:  2022-09-29

Review 4.  Non-coding RNAs and potential therapeutic targeting in cancer.

Authors:  Shusuke Toden; Timothy J Zumwalt; Ajay Goel
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-12-13       Impact factor: 10.680

5.  miRNA nanotherapeutics: potential and challenges in respiratory disorders.

Authors:  Meenu Mehta; Dinesh K Chellappan; Peter R Wich; Nicole G Hansbro; Philip M Hansbro; Kamal Dua
Journal:  Future Med Chem       Date:  2020-04-09       Impact factor: 3.808

Review 6.  Nanoparticle-Based Delivery of Tumor Suppressor microRNA for Cancer Therapy.

Authors:  Clodagh P O'Neill; Róisín M Dwyer
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

Review 7.  Recent applications and strategies in nanotechnology for lung diseases.

Authors:  Wenhao Zhong; Xinyu Zhang; Yunxin Zeng; Dongjun Lin; Jun Wu
Journal:  Nano Res       Date:  2021-01-08       Impact factor: 8.897

Review 8.  Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.

Authors:  Shruti Rawal; Mayur Patel
Journal:  Nanomicro Lett       Date:  2021-06-12

9.  Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.

Authors:  Alastair F Breen; David Scurr; Maria Letizia Cassioli; Geoffrey Wells; Neil R Thomas; Jihong Zhang; Lyudmila Turyanska; Tracey D Bradshaw
Journal:  Int J Nanomedicine       Date:  2019-12-05

10.  miR-4634 augments the anti-tumor effects of RAD001 and associates well with clinical prognosis of non-small cell lung cancer.

Authors:  Sile Liu; Hongjing Zang; Hongmei Zheng; Weiyuan Wang; Qiuyuan Wen; Yuting Zhan; Yang Yang; Yue Ning; Haihua Wang; Songqing Fan
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.